
Becton, Dickinson and Company BDX
$ 145.34
-2.78%
Quarterly report 2025-Q4
added 02-09-2026
Becton, Dickinson and Company Accounts Payables 2011-2026 | BDX
Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.Main types of accounts payable
| Type of liability | Example |
|---|---|
| To suppliers and contractors | Goods received but not yet paid for |
| Taxes and fees | VAT, income tax, etc., not paid on time |
| Salaries | Employee wages not paid |
| To budgets | Insurance contributions to funds not paid |
| To founders | Founders provided borrowed funds |
| To banks | Overdue loan payments |
| Other | Fines, penalties, forfeits, customer prepayments, etc. |
Impact on the company's financial performance
- Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios - Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence - Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals) - Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated
Annual Accounts Payables Becton, Dickinson and Company
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.97 B | 1.9 B | 1.64 B | 1.7 B | 1.74 B | 1.36 B | 1.09 B | 1.11 B | 797 M | 665 M | 631 M | 401 M | 333 M | 350 M | 305 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.97 B | 305 M | 1.07 B |
Quarterly Accounts Payables Becton, Dickinson and Company
| 2025-Q4 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.79 B | - | - | - | 1.36 B | - | - | - | 1.09 B | - | - | - | 1.11 B | - | - | - | 797 M | - | - | - | 665 M | - | - | - | 631 M | - | - | - | 401 M | - | - | - | 333 M | - | - | - | 350 M | - | - | - | 305 M | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.79 B | 305 M | 803 M |
Accounts Payables of other stocks in the Medical instruments industry
| Issuer | Accounts Payables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Atrion Corporation
ATRI
|
6.63 K | - | - | $ 810 M | ||
|
Ekso Bionics Holdings
EKSO
|
1.43 M | $ 11.16 | -0.49 % | $ 27.1 M | ||
|
ICU Medical
ICUI
|
154 M | $ 116.04 | -4.11 % | $ 2.86 B | ||
|
The Cooper Companies
COO
|
300 M | $ 62.28 | -1.28 % | $ 12.4 B | ||
|
Microbot Medical
MBOT
|
511 K | $ 2.05 | -2.6 % | $ 93.9 M | ||
|
Milestone Scientific
MLSS
|
780 K | $ 0.3 | -8.8 % | $ 24.6 M | ||
|
iRhythm Technologies
IRTC
|
2.26 M | $ 121.29 | -3.31 % | $ 3.88 B | ||
|
Haemonetics Corporation
HAE
|
67 M | $ 59.07 | -1.14 % | $ 2.97 B | ||
|
electroCore
ECOR
|
2.71 M | $ 6.25 | 1.63 % | $ 53 K | ||
|
Pulse Biosciences
PLSE
|
2.78 M | $ 20.99 | -3.85 % | $ 1.41 B | ||
|
Repro Med Systems
KRMD
|
2.27 M | $ 4.03 | -1.23 % | $ 186 M | ||
|
Intuitive Surgical
ISRG
|
255 M | $ 450.66 | -3.43 % | $ 161 B | ||
|
STAAR Surgical Company
STAA
|
11.6 M | $ 25.96 | -2.77 % | $ 1.29 B | ||
|
Glaukos Corporation
GKOS
|
13.4 M | $ 115.82 | -3.23 % | $ 5.61 B | ||
|
STERIS plc
STE
|
281 M | $ 211.72 | -3.82 % | $ 20.9 B | ||
|
Teleflex Incorporated
TFX
|
130 M | $ 135.79 | 0.21 % | $ 6.06 B | ||
|
Masimo Corporation
MASI
|
253 M | $ 178.45 | -0.03 % | $ 9.51 B | ||
|
InfuSystem Holdings
INFU
|
8.34 M | $ 9.83 | -3.44 % | $ 203 M | ||
|
Merit Medical Systems
MMSI
|
60.6 M | $ 64.63 | -3.16 % | $ 3.82 B | ||
|
Utah Medical Products
UTMD
|
911 K | $ 66.05 | -0.85 % | $ 214 M | ||
|
West Pharmaceutical Services
WST
|
254 M | $ 294.0 | 0.68 % | $ 21.3 B | ||
|
Envista Holdings Corporation
NVST
|
192 M | $ 25.98 | -1.96 % | $ 4.36 B | ||
|
DENTSPLY SIRONA
XRAY
|
300 M | $ 11.49 | -2.5 % | $ 2.29 B | ||
|
Retractable Technologies
RVP
|
5.34 M | $ 0.62 | -3.12 % | $ 18.6 M | ||
|
Pro-Dex
PDEX
|
4.61 M | $ 50.62 | -1.73 % | $ 166 M | ||
|
LeMaitre Vascular
LMAT
|
3.65 M | $ 109.67 | -2.43 % | $ 2.48 B | ||
|
Predictive Oncology
POAI
|
1.84 M | - | - | $ 31.1 M | ||
|
BioLife Solutions
BLFS
|
3.57 M | $ 20.33 | -2.73 % | $ 937 M | ||
|
Stereotaxis
STXS
|
4.77 M | $ 1.78 | -4.56 % | $ 162 M | ||
|
Baxter International
BAX
|
999 M | $ 16.99 | -5.35 % | $ 8.72 B | ||
|
ResMed
RMD
|
159 M | $ 212.65 | -1.99 % | $ 31.1 B | ||
|
AtriCure
ATRC
|
25.3 M | $ 27.56 | -3.23 % | $ 1.32 B | ||
|
Harvard Bioscience
HBIO
|
3.65 M | $ 6.25 | -3.1 % | $ 277 M | ||
|
NeuroMetrix
NURO
|
363 K | - | 5.05 % | $ 9.02 M | ||
|
AngioDynamics
ANGO
|
33.3 M | $ 10.59 | -3.55 % | $ 433 M | ||
|
Nephros
NEPH
|
873 K | $ 3.27 | -1.51 % | $ 34 M | ||
|
OraSure Technologies
OSUR
|
6.52 M | $ 2.95 | -2.16 % | $ 217 M | ||
|
Repligen Corporation
RGEN
|
19.6 M | $ 112.82 | -3.93 % | $ 6.29 M |